Efficacy of Percutaneous Ethanol Injection Therapy in Korean with Hepatocellular Carcinoma.
- Author:
Hyoun Woo KANG
1
;
Yoon Jun KIM
;
Kang Mo KIM
;
Jung Mook KANG
;
Su Hwan KIM
;
Jin Hyun KIM
;
Won Jae YOON
;
Jung Hwan YOON
;
Yong Bum YOON
;
Hyo Suk LEE
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. hsleemd@snu.ac.kr
- Publication Type:Original Article ; English Abstract
- Keywords:
Carcinoma;
hepatocellular;
Percutaneous ethanol injection;
Survival;
Recurrence
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Carcinoma, Hepatocellular/mortality/*therapy;
Ethanol/*administration & dosage;
Humans;
Injections, Intralesional;
Korea;
Liver Neoplasms/mortality/*therapy;
Male;
Middle Aged;
Neoplasms, Multiple Primary/mortality/therapy;
Survival Rate
- From:The Korean Journal of Gastroenterology
2003;42(6):502-509
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Percutaneous ethanol injection therapy (PEIT) is widely used for the treatment of hepatocellular carcinoma (HCC). However, its long-term therapeutic efficacy is not verified in Korea, one of hepatitis B virus (HBV) endemic areas. Thus, this study was to assess its efficacy and prognostic factors affecting tumor-free survival following PEIT in Korean HCC patients. METHODS: From 1997 to 1999, 100 consecutive patients who had 1 to 3 HCC nodules of maximum diameter less than 3 cm and underwent PEIT were enrolled. Therapeutic efficacy, overall and tumor-free survival rates were assessed during follow-up periods. RESULTS: In 83 patients, HCC nodules were completely ablated by PEIT. The cumulative 1, 2, and 3 year overall survival rates were 98%, 96%, and 88%, respectively. The cumulative 1, 2, and 3 year tumor-free survival rates were 73%, 50%, and 37%, respectively. Larger tumors (> or = were associated with a higher local recurrence rate. CONCLUSIONS: These results demonstrate that PEIT is therapeutically useful in patients with HCC less than 4 in number and less than 3 cm in diameter. However, since multiple or large tumors are associated with low tumor-free survival or high local recurrence rates, PEIT for these tumors and the subsequent post-treatment follow-up should be performed carefully.
